Morocco has one of the largest population of heart failure (HF) patients in the world; yet only limited information is available about HF in Morocco. In May 2016, a new version of the European Society of Cardiology (ESC) Guidelines for the management of heart failure (HF) was released.
The objectives of the study were to evaluate pharmacotherapy prescription in patients with HFrEF and impact of adherence on prognosis.
Transversal retrospective study conducted between May 2006 and June 2019 including all patients beyond the age of 14 with HFrEF followed-up in the therapeutic unit of HF of cardiology Department of Ibn Rochd University hospital. We studied betablocker, Angiotensin converting enzyme inhibitors (ACE-I), Angiotensin receptor blockers (ARB), Mineralocorticoides receptor antagonists (MRA) prescription and correlation with symptoms and prognostic features. Data were collected on Excel and analyzed using SPSS 2.0 software.
Our population included 3412 patients, mean age 64.92±12.95 yo, 63.7% of patients were male. Regarding cardiovascular risk factors: hypertension was represented in 38.9%, diabetes mellitus in 30.4%, dyslipidemia in 9.9%, tobacco use in 31.9%. Regarding comorbidities: 10.1% of patients had history of stroke and 5.5% history of end-stage chronic kidney disease. Regarding etiologies of HFrEF: ischemic heart disease in 76.81%, dilated cardiomyopathy in 13.47%, valvular heart disease in 4.83%, chemotherapy induced cardiomyopathy in 2.38%. Adherence to pharmacotherapy was evaluated as follows: 86.98% to betablocker, 80.04% to ACE-I, 56.7% to MRA. Mean HR was 62 bpm±16, mean SBP was 128mmHg±23, mean DBP was 74mmHg±13. 74% of all of our patients were receiving optimal medical therapy according to ESC 2016 guidelines. Hospitalization for HF rate was 46.37% and overall mortality was 8.1%.
Our registry shows an appropriate adherence to pharmacological recommendations from ESC HF Guidelines.
Le texte complet de cet article est disponible en PDF.
Publié par Elsevier Masson SAS.